Too often, critics greatly exaggerate price differences between the U.S. and other countries to create an erroneous impression that medicines are a major driver of U.S. health care cost growth – ignoring that medicines account for a small share of health spending differences between the U.S. and other countries. They also fail to acknowledge the ramifications of centralized price control policies other countries use to achieve whatever price differences do exist.
We’ve been exploring profiles of patients managing different chronic conditions like cancer and rheumatoid arthritis and the burdensome out-of-pocket costs they face. Unfortunately, for many like Eric and Rebecca, health insurance exchange plans may be putting patient access to needed medicines at risk.
Meet Chloe. Chloe is a 35-year-old retail clerk, living in California. Chloe earns $1,653.25 a month – meaning she qualifies for additional cost-sharing subsidies when purchasing a silver plan through the health insurance exchange. And like many of the nearly 44 million Americans managing a mental health condition, she uses medication to treat her bipolar affected disorder.
Patents are critical to the innovation ecosystem, and the lifeblood of the biopharmaceutical industry. Protecting and enforcing them is essential to keeping the engine of scientific discovery running for patients.
Over the past few months, a wide range of stakeholders – including universities, employers, and the biopharmaceutical industry – have raised concerns that the Innovation Act, legislation designed to address abusive patient litigation, could have unintended consequences for patients. If intellectual property is not adequately protected, innovative research becomes more difficult which in turn impacts biopharmaceutical companies’ ability to develop new medicines for patients.
Ask About Adherence is a blog series featuring Q&A’s with experts on medication adherence. But, this week we are straying from our regular format to announce that the PhRMA Foundation has awarded four research grants as part of its Young Investigator Adherence Grant Program.
Established in 2012, the Young Investigator Adherence Grant Program was created by the PhRMA Foundation to support research conducted by predoctoral candidates, postdoctoral fellows, and junior faculty to advance knowledge of innovative and effective approaches to improve medication adherence.
In case you missed it, a special report, “Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care,” published online yesterday in the American Association for Cancer Research (AACR) journal Clinical Cancer Research. Authored by Turning the Tide Against Cancer co-conveners, the report proposes four key policy recommendations to further the national dialogue on accelerating the delivery of patient-centered, high-quality cancer research and care.
Earth Day provides us all with an opportunity to consider the role each of us can play in protecting the Earth’s natural resources. The nation’s innovative biopharmaceutical companies spend substantial time and resources on identifying ways to improve the efficiency and effectiveness of not just their R&D processes but also their manufacturing processes with an increased focus on green chemistry. Forthcoming reports from Tufts Center for the Study of Drug Development and Deloitte describe green manufacturing practices among biopharmaceutical companies large and small. The biopharmaceutical industry has long been committed to environmentally responsibility and many publish corporate responsibility reports that provide information not just on their impact on the environment but also the steps they are taking to reduce their carbon footprint and environmental impact.
Spending on retail prescription medicines has consistently accounted for just 10 percent of health care spending, even though biopharmaceutical companies have brought more than 500 medicines to U.S. patients in the past 15 years. That's because the marketplace for prescription medicines is unlike any other part of the U.S. health care system. High utilization rates of generics, competition among brand-name medicines and aggressive tactics by insurers to negotiate prices all help to keep costs under control.
Earlier today, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced that its member companies have invested more than $600 billion in the search for new treatments and cures since 2000 – including an estimated $51.2 billion in 2014 alone.
This is an exciting time for biomedical research as innovation is at an all-time high. To continue this positive trajectory, researchers need training opportunities that embrace team science approaches and cross all stakeholder sectors.
Over the past few weeks, we’ve discussed how Medicare Part D helps patients with a number of different conditions including Parkinson’s, artery plaque, congestive heart failure, chronic obstructive pulmonary disease and dehydration save, just by adhering to the medicines they get through their Part D plans. This week, we’re highlighting one way Medicare aims to improve the use of medications and adherence in Part D: medication therapy management (MTM).